Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Graft-versus-host disease therapy - Human Life CORD Japan

Next Previous
X
Search
Drug Profile

Graft-versus-host disease therapy - Human Life CORD Japan

Alternative Names: Graft-versus-host disease umbilical cord MSCs - Human Life CORD Japan

Latest Information Update: 16 Mar 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Human Life CORD Japan
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Graft-versus-host disease

Most Recent Events

  • 24 Feb 2022 Graft-versus-host disease therapy - Human Life CORD Japan is available for licensing as of 24 Feb 2022. https://www.humanlifecord.com/en/business.html
  • 01 Dec 2021 Phase-I clinical trials in Graft-versus-host disease in Japan (Parenteral) (Human Life Cord Japan pipeline, December 2021)
  • 01 Dec 2021 Human Life Cord Japan plans a phase II clinical trial for Graft-versus-host disease (Human Life Cord Japan, December 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top